In the last trading session, 2,235,824 Nuvation Bio Inc. (NYSE:NUVB) shares changed hands as the company’s beta touched 0. With the company’s per share price at $9.67 changed hands at -$0.62 or -0.06% during last session, the market valuation stood at $2.11 Billion. NUVB’s last price was a discount, traded about -57.5% off its 52-week high of $15.23. The share price had its 52-week low at $8.56, which suggests the last value was 11.48% up since then. When we look at Nuvation Bio Inc.’s average trading volume, we note the 10-day average is 1.28 Million shares, with the 3-month average coming to 817.52 Million.
Analysts gave the Nuvation Bio Inc. (NUVB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.5. If we narrow down to specifics, the data shows that none out of 6 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended NUVB as a Hold, 6 felt it is a Buy and none rated the stock as Underweight. Nuvation Bio Inc.’s EPS for the current quarter is expected to be -$0.1.
Nuvation Bio Inc. (NYSE:NUVB) trade information
Although NUVB has turned red as seen at the end of in last trading. With action -6.03%, the performance over the past five days has been red. The jump to weekly highs of $11.81 on Monday, Jun 14 added 18.12% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.17%, with the 5-day performance at -0.17% in the red. However, in the 30-day time frame, Nuvation Bio Inc. (NYSE:NUVB) is -0.19% down. Looking at the short shares, we see there were 4.74 Million shares sold at short interest cover period of 0.01 days.
The consensus price target for the stock as assigned by Wall Street analysts is $17.8, meaning bulls need an upside of 84.07% from its current market value. According to analyst projections, NUVB’s forecast low is $15 with $21 as the target high. To hit the forecast high, the stock’s price needs a +117.17% upsurge from its current level, while the stock would need to tank 55.12% for it to hit the projected low.
Nuvation Bio Inc. (NUVB) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. The 2021 estimates are for Nuvation Bio Inc. earnings to decrease by -100%, but the outlook for the next 5-year period is at 0% per year.
Nuvation Bio Inc. (NYSE:NUVB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 27.69% of Nuvation Bio Inc. shares while 67.25% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93%. There are 82 institutions holding the Nuvation Bio Inc. stock share, with FMR, LLC the top institutional holder. As of Mar 30, 2021, the company held 14.83% of the shares, roughly 32.28 Million NUVB shares worth $337.37 Million.
EcoR1 Capital, LLC holds the second largest percentage of outstanding shares, with 6.09% or 13.25 Million shares worth $138.43 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 2458173 shares estimated at $25.69 Million under it, the former controlled 1.13% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 0.97% of the shares, roughly 2.1 Million shares worth around $21.95 Million.